IL-17i Ixekizumab (IXE) continuation superior to withdrawal in preventing relapse in PsA
● Withdrawal resulted in relapse at median 22 wk
● Continuation vs withdrawal 38% vs 85% relapse
● 96% regained control after reinstating IXE
Jose Scher #ReviewCourse @RheumNow #ACR22
● Withdrawal resulted in relapse at median 22 wk
● Continuation vs withdrawal 38% vs 85% relapse
● 96% regained control after reinstating IXE
Jose Scher #ReviewCourse @RheumNow #ACR22
